166 related articles for article (PubMed ID: 17354650)
1. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
3. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
[TBL] [Abstract][Full Text] [Related]
4. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
5. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
6. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
Betz UA; Fischer R; Kleymann G; Hendrix M; Rübsamen-Waigmann H
Antimicrob Agents Chemother; 2002 Jun; 46(6):1766-72. PubMed ID: 12019088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
[TBL] [Abstract][Full Text] [Related]
8. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
9. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
10. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
11. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
12. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
13. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
14. HSV antivirals - current and future treatment options.
Birkmann A; Zimmermann H
Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
[TBL] [Abstract][Full Text] [Related]
15. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
16. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
17. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
18. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.
Biswas S; Jennens L; Field HJ
Antiviral Res; 2007 Jul; 75(1):30-5. PubMed ID: 17175035
[TBL] [Abstract][Full Text] [Related]
19. Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Earwood J; Clark JR; Li Y; Mishra P; Li C; Nayak BP; Miller AT; Wu TY; Cooke MP; Valiante NM
Antivir Chem Chemother; 2014 Apr; 23(5):189-96. PubMed ID: 23232327
[TBL] [Abstract][Full Text] [Related]
20. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
